minocycline hydrochloride · Journey · NDA 219015
Emrosi
Earliest generic entry, as listed
7 Jan 2039
Blocked by patent: US 10905664, US 11191740, US 11364212, US 12594252. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10905664 | use U-4043 | 7 Jan 2039 |
| US 11191740 | use U-4043 | 7 Jan 2039 |
| US 11364212 | use U-4043 | 7 Jan 2039 |
| US 12594252 | use U-4043 | 7 Jan 2039 |
Exclusivities · 1 unexpired
| NP | new product | 1 Nov 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219015 · 001 · RLD | capsule, extended release, oral | EQ 40MG BASE | 7 Jan 2039 |